September 8-12, 2017, Kathy Barnard attended the ESMO 2017 Congress, European Society for Medical Oncology, in Madrid Spain. In partnership with the European Association for Cancer Research, ESMO brought cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back. This exciting partnership creates a unique cancer congress in Europe with huge scientific reach and the true potential to improve the lives of cancer patients.
With her, Kathy brought home the latest in news about melanoma and other skin cancers, as summarized in this report: ESMO 2017 Congress – Melanoma Highlights.
Adjuvant dabrafenib plus trametinib significantly lowers risk of death in stage III BRAF V600–mutated melanoma
BRIM8 data shows benefit with adjuvant vemurafenib in resected BRAFV600 positive melanoma
Nivolumab bests ipilimumab as adjuvant therapy in resected melanoma
Article from ESMO Daily Reporter
Practice-changing phase III data in melanoma patients cause excitement at a Presidential Symposium
Links to Press Releases
ESMO 2017 Press Release: Combination Targeted Adjuvant Therapy Doubles Relapse-free Survival in Stage III Melanoma
ESMO 2017 Press Release: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma